Indeed, IFNα treatment in the context of multiple sclerosis and chronic myeloid leukemia has been associated with neurotoxicity, which is in contrast to IFNβ that is used for the treatment of multiple sclerosis [49,50]. This evidence concerns the gene IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive.